Who Paid My Doc Search
Menu
Organisation paid for research Program year 2025 Source: CMS Open Payments

Pinnacle Clinical Research

Neither a doctor nor a teaching hospital

Research payments

$4,051,846

582 payments

Through program year 2025, Pinnacle Clinical Research is reported as receiving $4,051,846 in research payments, across 582 payments.

By program year

7 rows
Year Kind Amount Payments
2025 Research $730,449 382
2024 Research $955,742 36
2023 Research $516,210 34
2022 Research $216,151 10
2021 Research $36,244 10
2020 Research $698,073 30
2019 Research $898,976 80

Breakdown

Who paid Research payments · program years 2019–2025
  1. E.R. Squibb & Sons, L.L.C. $1,406,089 13 payments
  2. Takeda Pharmaceuticals U.S.A., Inc. $564,014 30 payments
  3. Boehringer Ingelheim International GmbH $560,766 374 payments
  4. AstraZeneca UK Limited $373,271 7 payments
  5. AstraZeneca Pharmaceuticals LP $308,287 6 payments
  6. Incyte Corporation $275,029 13 payments
  7. Amgen Inc. $251,713 5 payments
  8. GlaxoSmithKline, LLC. $171,499 39 payments
  9. Novo Nordisk AS $127,054 85 payments
  10. Allergan Inc. $5,301 4 payments
Studies the money was for Research payments · program years 2019–2025
  1. A Phase 2B Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Safety and Efficacy of Bms-986036 Peg-Fgf21 in Adults With Nonalcoholic Steatohepatitis Nash and Stage 3 Liver Fibrosis $516,945 2 payments
  2. An oral inhibitor of tyrosine kinase 2 (TYK2) that binds to the JH2 pseudokinase domain, resulting in highly selective TYK2 kinase activity compared with the other homologous proteins in the Janus kinase (JAK) family of nonreceptor tyrosine kinases (JAK1, JAK2, and JAK3) $483,650 19 payments
  3. A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis $405,704 267 payments
  4. A Phase 2B Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Safety and Efficacy of Bms-986036 (Peg-Fgf21) in Adults With Nonalcoholic Steatohepatitis (Nash) and Stage 3 Liver Fibrosis $332,766 4 payments
  5. A Randomised, Double-blind, Placebo-controlled, Multi-centre Phase 2b Study to Evaluate the Efficacy, Safety and Tolerability of AZD2693 in Participants with Non-cirrhotic Non-alcoholic Steatohepatitis (NASH) with Fibrosis Who Are Carriers of the PNPLA3 rs738409 148M Risk Allele $308,287 6 payments
  6. A Phase 2B Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Safety and Efficacy of Bms-986036 Peg-Fgf21 in Adults With Nonalcoholic Steatohepatitis Nash and Compensated Liver Cirrhosis $278,101 2 payments
  7. A Phase 2B Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Safety and Efficacy of Bms-986036 (Peg-Fgf21) in Adults With Nonalcoholic Steatohepatitis (Nash) and Compensated Liver Cirrhosis $276,623 4 payments
  8. A Phase I, Single Dose, Non-Randomised, Multicentre, Open-Label, Parallel Group Study to Investigate the Effect of Hepatic Impairment on the Pharmacokinetics, Safety and Tolerability of Camizestrant (AZD9833, a Next Generation, Oral Selective Estrogen Receptor Degrader) in Post-menopausal Female Subjects $241,596 3 payments
  9. A Phase 1 Study to Evaluate the Pharmacokinetics, Safety, and Pharmacodynamics of INCB000928 in Participants With Impaired Renal Function and Hemodialysis $216,151 10 payments
  10. 17 B-Hydroxysteroid Dehydrogenase Type 13 Minimization for the Treatme $168,749 36 payments

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.

Provenance

Source: CMS Open Payments · through program year 2025

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record